drug · gene
arlocabtagene autoleucel
Phase 3updated 5mo agoby Bristol-Myers Squibb Co🔗 ChEMBL
Phase 3community read0 votes
Gene drug with a maximum clinical stage of Phase 3 (across all indications), with 2 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying arlocabtagene autoleucel
News(3)
- BMS clinches pivotal win for myeloma CAR T in ‘key derisking event’Bristol Myers Squibb is positioning arlo-cel for quadruple-class exposed patients, which could help reduce competition with an upcoming multiple myeloma CAR T therapy from Gilead Sciences, accordin…biospace · 24d ago
- Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapyOne analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a ke…biopharma_dive · 25d ago
- Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpointA pivotal trial of Bristol Myers Squibb’s GPRC5D-directed CAR-T cell therapy has hit its primary endpoint, furthering the drugmaker’s efforts to challenge Johnson & Johnson for the post-BCMA multip…fiercebiotech · 25d ago
Data sources
last refreshed 20m ago
Found something off?
comments(0)
5-min edit window · permanent after that